Orexo develops improved pharmaceuticals and digital therapeutics addressing unmet needs mainly within the growing space of addiction. The products are commercialized by Orexo in the US or via partners worldwide. The main market today is the American market for buprenorphine/naloxone products, where Orexo commercialize its lead product Zubsolv® for treatment of opioid use disorder. Total net sales for 2018 amounted to SEK 783.1 million and the number of employees was 129.
Our drug delivery technologies improve pharmaceuticals
Orexo develops improved products by combining well-known and well-documented substances with in-house innovative drug delivery technologies.
Developed 4 products approved worldwide
Orexo has developed four products from concept to patient. The products have been approved in multiple markets and helped patients benefit from improved drugs worldwide.
Strategic focus on product expansion
One of Orexo’s objectives for long-term growth is to broaden the US commercial platform, by M&A transactions, to leverage scale and expand sales.
Key market characterized by strong growth
In the US the #opioidcrisis is accelerating and in 2017 70,200 Americans died of an overdose, mainly caused by use of opioids. There is a great need for treatment and the buprenorphine/naloxone market grew by more than 14 percent in 2018.
Embracing all aspects of opioid addiction
Orexo’s pipeline contains development projects with a primary therapeutic focus around opioid addiction in all phases, from prevention to treatment.